Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-088593
Filing Date
2024-07-31
Accepted
2024-07-31 16:15:30
Documents
70
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sage-20240630.htm   iXBRL 10-Q 2719088
2 EX-10.1 sage-ex10_1.htm EX-10.1 164475
3 EX-10.2 sage-ex10_2.htm EX-10.2 56837
4 EX-10.3 sage-ex10_3.htm EX-10.3 72885
5 EX-10.4 sage-ex10_4.htm EX-10.4 57709
6 EX-10.5 sage-ex10_5.htm EX-10.5 33762
7 EX-10.6 sage-ex10_6.htm EX-10.6 10796
8 EX-31.1 sage-ex31_1.htm EX-31.1 10981
9 EX-31.2 sage-ex31_2.htm EX-31.2 10960
10 EX-32.1 sage-ex32_1.htm EX-32.1 9082
11 GRAPHIC img94125284_0.jpg GRAPHIC 411619
  Complete submission text file 0000950170-24-088593.txt   11871354

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sage-20240630.xsd EX-101.SCH 1280695
73 EXTRACTED XBRL INSTANCE DOCUMENT sage-20240630_htm.xml XML 2065430
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36544 | Film No.: 241162143
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)